港股异动 | 中慧生物-B(02627)涨超8% 四价流感病毒亚单位疫苗入选商保初步审查名单市场稀缺性显著

智通财经

Sep 16, 2025

智通财经APP获悉，中慧生物-B(02627)涨超8%，截至发稿，涨7.49%，报51.25港元，成交额1846.3万港元。

消息面上，近日，中慧生物-B发布公告，公司董事会欣然宣布，中国国家药品监督管理局(国家药监局)已批准集团针对6-35月龄人群的四价流感病毒亚单位疫苗的新药申请。该款疫苗成为中国首款且唯一一款获批上市的全人群全剂量四价流感病毒亚单位疫苗。该产品在传统病毒裂解疫苗的基础上进行重大升级，具有保护全面、组分抗原纯度高、不良反应风险低等优势。

智通财经APP在《国内首款全人群四价流感亚单位疫苗获批，中慧生物-B(02627)商业化放量在即》中指出，作为国内预防用生物制品一类新药，四价流感病毒亚单位疫苗已于今年8月进入商业保险创新药目录初步形式审查名单，且为名单中唯一入选的疫苗产品，稀缺性显著，预计上市后将有效填补相应市场空白。

目前国内市场上主流产品为第二代普通裂解流感疫苗，而中慧生物-B开发的“亚单位”流感疫苗属于第三代技术路线。其在裂解疫苗基础上进一步优化生产工艺，仅提取病毒表面有效抗原成分——血凝素(HA)和神经氨酸酶(NA)，显著提高抗原纯度，降低杂质含量，在安全性、免疫效果和整体品质方面具备明显优势。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2567786151"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2567786151\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2567786151?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-09-16 11:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567786151","market":"sh","top_or_hot":-1,"title":"港股异动 | 中慧生物-B(02627)涨超8% 四价流感病毒亚单位疫苗入选商保初步审查名单 市场稀缺性显著","media":"智通财经","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/02627\">中慧生物-B</a>(02627)涨超8%，截至发稿，涨7.49%，报51.25港元，成交额1846.3万港元。</p><p>消息面上，近日，中慧<a href=\"https://laohu8.com/S/000504\">生物</a>-B发布公告，公司董事会欣然宣布，中国国家药品监督管理局(国家药监局)已批准集团针对6-35月龄人群的四价流感病毒亚单位疫苗的新药申请。该款疫苗成为中国首款且唯一一款获批上市的全人群全剂量四价流感病毒亚单位疫苗。该产品在传统病毒裂解疫苗的基础上进行重大升级，具有保护全面、组分抗原纯度高、不良反应风险低等优势。</p><p>智通财经APP在《国内首款全人群四价流感亚单位疫苗获批，中慧生物-B(02627)商业化放量在即》中指出，作为国内预防用生物制品一类新药，<span>四价流感病毒亚单位</span>疫苗已于今年8月进入商业保险创新药目录初步形式审查名单，且为名单中唯一入选的疫苗产品，稀缺性显著，预计上市后将有效填补相应市场空白。</p><p>目前国内市场上主流产品为第二代普通裂解流感疫苗，而中慧生物-B开发的“亚单位”流感疫苗属于第三代技术路线。其在裂解疫苗基础上进一步优化生产工艺，仅提取病毒表面有效抗原成分——血凝素(HA)和神经氨酸酶(NA)，显著提高抗原纯度，降低杂质含量，在安全性、免疫效果和整体品质方面具备明显优势。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 中慧生物-B(02627)涨超8% 四价流感病毒亚单位疫苗入选商保初步审查名单 市场稀缺性显著</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 中慧生物-B(02627)涨超8% 四价流感病毒亚单位疫苗入选商保初步审查名单 市场稀缺性显著\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-16 11:34 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1345664.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，中慧生物-B(02627)涨超8%，截至发稿，涨7.49%，报51.25港元，成交额1846.3万港元。消息面上，近日，中慧生物-B发布公告，公司董事会欣然宣布，中国国家药品监督管理局(国家药监局)已批准集团针对6-35月龄人群的四价流感病毒亚单位疫苗的新药申请。该款疫苗成为中国首款且唯一一款获批上市的全人群全剂量四价流感病毒亚单位疫苗。该产品在传统病毒裂解疫苗的基础上进行重大...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1345664.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159646","symbol_name":"疫苗","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1345664.html","article_id":"2567786151","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567786151","pubTimestamp":1757993641,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP在《国内首款全人群四价流感亚单位疫苗获批，中慧生物-B商业化放量在即》中指出，作为国内预防用生物制品一类新药，四价流感病毒亚单位疫苗已于今年8月进入商业保险创新药目录初步形式审查名单，且为名单中唯一入选的疫苗产品，稀缺性显著，预计上市后将有效填补相应市场空白。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159646":"疫苗","02627":"中慧生物-B","BK4614":"Manus概念股","YANG":"三倍做空富时中国ETF-Direxion","BK1161":"生物科技","HSCEI":"国企指数"},"translate_title":"Changes in Hong Kong stocks | Zhonghui Bio-B (02627) rose more than 8%. The quadrivalent influenza virus subunit vaccine was selected into the preliminary review list of commercial insurance, and the market is scarce","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1.5,"HSCEI":1.5,"YANG":1.5,"02627":1.5},"content_text":"智通财经APP获悉，中慧生物-B(02627)涨超8%，截至发稿，涨7.49%，报51.25港元，成交额1846.3万港元。消息面上，近日，中慧生物-B发布公告，公司董事会欣然宣布，中国国家药品监督管理局(国家药监局)已批准集团针对6-35月龄人群的四价流感病毒亚单位疫苗的新药申请。该款疫苗成为中国首款且唯一一款获批上市的全人群全剂量四价流感病毒亚单位疫苗。该产品在传统病毒裂解疫苗的基础上进行重大升级，具有保护全面、组分抗原纯度高、不良反应风险低等优势。智通财经APP在《国内首款全人群四价流感亚单位疫苗获批，中慧生物-B(02627)商业化放量在即》中指出，作为国内预防用生物制品一类新药，四价流感病毒亚单位疫苗已于今年8月进入商业保险创新药目录初步形式审查名单，且为名单中唯一入选的疫苗产品，稀缺性显著，预计上市后将有效填补相应市场空白。目前国内市场上主流产品为第二代普通裂解流感疫苗，而中慧生物-B开发的“亚单位”流感疫苗属于第三代技术路线。其在裂解疫苗基础上进一步优化生产工艺，仅提取病毒表面有效抗原成分——血凝素(HA)和神经氨酸酶(NA)，显著提高抗原纯度，降低杂质含量，在安全性、免疫效果和整体品质方面具备明显优势。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}